✦ LIBER ✦

Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: An extended follow-up

✍ Scribed by Elizabeth N. Skinner; David M. Boruta; Paola A. Gehrig; John F. Boggess; Wesley C. Fowler Jr.; Linda Van Le

Book ID: 113959917
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 94 KB
Volume: 98
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2005.04.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Experience with single-agent paclitaxel

Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer

✍ John P. Micha; Bram H. Goldstein; Julie A. Mattison; Kathy Bader; Cheri Graham; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Weekly paclitaxel and carboplatin follow

Weekly paclitaxel and carboplatin followed by topotecan (TC-TP), as first-line therapy for patients with advanced epithelial ovarian cancer (AOC) suboptimally debulked. Updated preliminary results

✍ J.A. Arranz Arija; R. Gonzalez-Beca; A. Velasco; M.M. Perez; P. Borrega; M. Bola 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 363 KB

Ten-year follow-up of a phase 2 study of

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

✍ Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced‐stage epithelial ovarian cancer (EOC) who were receiving dose‐intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched

Phase 1/2 study of weekly paclitaxel wit

Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer

✍ G. Falchook; B. Goff; R. Kurzrock; H. Gray; L. Martin; R. Coleman; H. Xiao; X. Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Effect of adjuvant paclitaxel and carbop

Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: A population-based cohort study of all patients in western Sweden with long-term follow-up

✍ MARGARETHA ÅKESON; BRITT-MARIE ZETTERQVIST; KALLE DAHLLÖF; MATS BRÄNNSTRÖM; GYÖR 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 237 KB